Tag Index  /  Showing 1 - 4 of 4 results for “Anne Wojcicki”

Government Healthcare

FDA Greenlights 23andMe and Opens New Era for Consumer DNA Info

It was a much-needed breakthrough when the FDA last week OK'd personal genomics company 23andMe selling genetic tests directly to consumers. In 2013 the agency had banned the startup from releasing disease-related information. Now we should finally see a consumer-driven marketplace for genomic data.   More

Analytics & Data Bio & Life Sciences

23andMe’s Community Wants to Help, CEO Tells Genomics Researchers

At a genomics conference in February, 23andMe CEO Anne Wojcicki took the stage to make the case for the scientific importance of her consumer genetics platform. Wojcicki still has a grand vision for how the service could help advance our understanding of human health, even as she acknowledges that recent restrictions imposed on the company by the FDA have left her more cautious about growth plans for 23andMe.   More

Analytics & Data Bio & Life Sciences Business

23andMe’s FDA Battle Provokes Furious Debate

Medical researchers, genomics experts, and industry pundits took wildly divergent points of view in a media storm that erupted last week over FDA’s stern letter ordering 23andMe to stop marketing its Personal Genome Service. The agency cited concerns about “the public health consequences of inaccurate results.” Others say public access to genomic information is just the beginning of ongoing disruption in healthcare.   More

Bio & Life Sciences

Are Flash Sales Coming to Consumer Genomics?

Could consumers be persuaded to snatch up DNA sequences as must-have accessories? With former Gilt Groupe President Andy Page in a new leadership role, 23andMe might be able to swing that. The personal genetics company began late last year offering its Personal Genome service for $99 and set a goal to serve 1 million customers in 2013.   More